Stockscreener 앱 받기
27.39
3.28%
0.87
Alkermes Plc 주식(ALKS)의 최신 뉴스
Leading companies in this space include Aadi Bioscience, - openPR.com
Analysts Set Alkermes plc (NASDAQ:ALKS) Target Price at $41.85 - MarketBeat
Fed Watch: Is Alkermes plc stock undervalued right nowJuly 2025 Big Picture & Low Risk High Reward Trade Ideas - خودرو بانک
Pullback Watch: Will Alkermes plc outperform during market rallies2025 Pullback Review & Accurate Buy Signal Alerts - خودرو بانک
Rate Cut: What is the implied volatility of Alkermes plcJuly 2025 Market Mood & Weekly Chart Analysis and Trade Guides - خودرو بانک
Bearish Setup: What is the implied volatility of Alkermes plcJuly 2025 WrapUp & Fast Entry High Yield Tips - خودرو بانک
Alkermes' CFO Iain Brown passes away - MSN
Alkermes plc $ALKS Shares Acquired by Intech Investment Management LLC - MarketBeat
Whale Trades: Can Alkermes plc maintain sales growthJuly 2025 Update & Verified Entry Point Signals - خودرو بانک
Tech Rally: Is Alkermes plc stock technically oversoldJuly 2025 Closing Moves & Free Technical Confirmation Trade Alerts - خودرو بانک
Market Review: What chart patterns are forming on WM Technology Inc. Equity WarrantEarnings Risk Summary & Community Shared Stock Ideas - خودرو بانک
Alkermes (NASDAQ:ALKS) Earns "Neutral" Rating from HC Wainwright - MarketBeat
AQR Capital Management LLC Sells 279,276 Shares of Alkermes plc $ALKS - MarketBeat
Amundi Cuts Holdings in Alkermes plc $ALKS - MarketBeat
Alkermes (NASDAQ:ALKS) Reaches New 1-Year LowHere's Why - MarketBeat
Alkermes (NASDAQ:ALKS) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Alkermes Sees Unusually Large Options Volume (NASDAQ:ALKS) - MarketBeat
Acadian Asset Management LLC Has $29.10 Million Position in Alkermes plc $ALKS - MarketBeat
Baird Financial Group Inc. Purchases New Shares in Alkermes plc $ALKS - MarketBeat
Alkermes appoints Joshua Reed as new CFO effective Monday By Investing.com - Investing.com Australia
Alkermes appoints Joshua Reed as new CFO effective Monday - Investing.com India
Alkermes appoints new CFO - MSN
Alkermes says on Sept 9, unit granted Amneal rights to sell generic version of VivitrolSEC filing - MarketScreener
Alkermes Appoints Joshua Reed as New CFO - TipRanks
Alkermes plc Appoints Joshua Reed as Chief Financial Officer, Effective Date Is September 15, 2025 - MarketScreener
Alkermes Appoints Joshua Reed as Chief Financial Officer - Sharecast News
Alkermes (ALKS) Appoints Joshua Reed as New CFO - GuruFocus
Alkermes appoints Joshua Reed as chief financial officer - MarketScreener
30-Year Biotech Finance Veteran Joshua Reed Joins Alkermes as CFO After Bristol Myers Leadership - Stock Titan
While Shareholders of Alkermes (NASDAQ:ALKS) Are in the Black Over 5 Years, Those Who Bought a Week Ago Aren't so Fortunate - 富途牛牛
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program - Eastern Progress
Fred Alger Management LLC Takes $1.24 Million Position in Alkermes plc $ALKS - MarketBeat
Alkermes Announces Launch of 8th Annual Alkermes Pathways Resear - GuruFocus
Potential Impact on Alkermes (ALKS) from RFK Jr.'s Possible Depa - GuruFocus
How RFK Jr.'s Potential Exit Could Benefit Alkermes (ALKS) - GuruFocus
JP Morgan Maintains Neutral Rating for ALKS and Raises Price Tar - GuruFocus
December 2026 Options Now Available For Alkermes (ALKS) - Nasdaq
Can Alkermes plc stock outperform in a bear market2025 Risk Factors & Stepwise Trade Signal Guides - Lancaster City Council
HC Wainwright & Co. Reiterates Neutral Rating for ALKS | ALKS St - GuruFocus
Alkermes Announces Positive Phase 2 Study Results - MSN
Alkermes (NASDAQ:ALKS) Stock Rating Upgraded by Wells Fargo & Company - MarketBeat
Alkermes plc $ALKS Shares Acquired by Canada Pension Plan Investment Board - MarketBeat
Is Alkermes plc stock showing strong momentumJuly 2025 Spike Watch & Reliable Breakout Forecasts - 뉴스영
Alkermes stock hits 52-week low at 25.31 USD By Investing.com - Investing.com Canada
Alkermes (ALKS) Reports Promising Results from Phase 2 Narcoleps - GuruFocus
Alkermes reports positive phase 2 results for narcolepsy drug By Investing.com - Investing.com Canada
Takeda and Alkermes share OX2R drug data for narcolepsy - Yahoo Finance
Alkermes stock hits 52-week low at 25.31 USD - Investing.com
Alkermes (ALKS) Shows Progress in Narcolepsy Study, Faces Invest - GuruFocus
Alkermes : ALKS World Sleep 2025 Prepared Remarks 9 8 2025 FINAL - MarketScreener
0.05%
0.68%
자본화:
|
볼륨(24시간):